Omeros Stock Falls 12% After EMA Committee Reaffirms Negative Narsoplimab Opinion

Omeros Corp. (OMER) shares fell 12% to $16.53 after the European Medicines Agency's committee reaffirmed its negative opinion on narsoplimab for a specific treatment. The stock traded between $15.89 and $17.94. Omeros plans to provide access in Europe and continues U.S. commercialization of YARTEMLEA, approved by the FDA in 2025.

Original reporting
Published Oct 16, 2026, 3:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 6:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$OMER
Bearish
high confidence
Mentioned
$OMER
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$OMERBearishMed
01

Why it matters

A reaffirmed negative EMA stance reduces the likelihood of near-term EU approval, which can pressure valuation multiples for biotech programs even when the product is already FDA-approved in the U.S.

02

Market read

This is a direct regulatory catalyst tied to a same-day, double-digit stock move, making it actionable for traders focused on biotech approval risk.

03

What to watch

The article does not quantify any probability of appeal, resubmission, or alternative EU pathways; traders may be over-discounting without knowing next regulatory steps.

Relevance 8/10Novelty 6/10Timing: Friday session, immediate post-news reaction

Background

The EMA committee re-examined its June 2026 negative opinion on Omeros’ narsoplimab marketing authorization application for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).

Company-level read

Ticker impact

$OMERBearishHigh confidence
Context

Omeros shares fell 12% after the EMA committee reaffirmed a negative opinion on its narsoplimab marketing authorization application for TA-TMA.

Expected impact

Likely continued downside or elevated volatility as traders price in delayed or reduced European approval prospects.

Evidence & confidence

The article ties the same-day double-digit drop directly to the EMA committee reaffirming a negative opinion after re-examination, a clear near-term catalyst.

Market effects

Highlights regulatory risk for rare-disease biotech seeking EU marketing authorization, potentially weighing on sentiment for similar TA-TMA/hematology assets.

EU reimbursement and access expectations for the therapy are likely to remain constrained, affecting European biotech sentiment.

Reinforces that even after FDA approval, EU review outcomes can diverge, shaping global risk perception for cross-region commercialization.

Counterpoint

U.S. commercialization of YARTEMLEA continues, so the EMA negative opinion may be partially offset by ongoing U.S. revenue momentum and named-patient access efforts.

Key entities

  • Omeros Corp.

    NASDAQ-listed biotech whose narsoplimab (YARTEMLEA in the U.S.) faces a reaffirmed negative EMA opinion for TA-TMA.

  • European Medicines Agency (EMA) Committee for Medicinal Products for Human Use

    EU committee that reaffirmed a negative opinion after re-examination of Omeros’ marketing authorization application.

  • narsoplimab

    Therapy at the center of the EMA marketing authorization decision for TA-TMA.

Related articles

$OMERMed

OMER Stock Eyes Worst Day In Nearly 18 Months With European Yartemlea Setback, Paper Losses Hitting Shares

Omeros (OMER) shares are down, heading for their worst day in 18 months. The company delayed Q4 and 2027 sales guidance, citing uncertainty. A clinical trial for OMS527 was postponed to 2027 due to delays in acquiring study animals. Despite this, retail sentiment on Stocktwits turned bullish, focusing on Yartemlea's launch and a partnership with Novo Nordisk. OMER stock is down 22% year-to-date.

$OMERMed

Omeros (OMER) Q3 2026 Earnings Call Transcript

Omeros (OMER) reported Q3 2026 earnings with YARTEMLEA generating $35.9M in net sales, up 26% from Q2. GAAP net loss was $57.4M, but non-GAAP net income was $4.7M. The company reduced convertible notes and repurchased shares. YARTEMLEA saw increased adoption and reimbursement advantages.

$OMERMed

Why is Omeros stock sliding today?

Omeros (OMER) stock fell 10.4% in after-hours trading after reporting Q3 2026 results. The company reported a GAAP net loss of $57.4 million, or $0.79 per share, due to a $62.0 million non-cash loss. Adjusted EPS of $0.06 beat estimates, and revenue exceeded expectations. A negative opinion from the European Medicines Agency on narsoplimab also weighed on sentiment.

$OMERMedAI 8/10

Omeros falls 10% despite revenue beat

Omeros (NASDAQ:OMER) reported Q3 revenue of $41.8M, beating estimates, but shares fell 10% due to a widened GAAP net loss of $57.4M. Adjusted earnings were $0.06 per share, exceeding expectations. YARTEMLEA sales grew 30% sequentially. The company held $95.3M in cash as of Q3 2026.

$OMERMed

Omeros Corporation Reports Third Quarter 2026 Financial Results

OMEROS CORP (OMER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Omeros Corporation Reports Third Quarter 2026 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – November 16, 2026 – Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third q